# A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity

> **NCT03032783** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 51 (actual)

## Conditions studied

- Hematopoietic and Lymphoid Cell Neoplasm

## Interventions

- **RADIATION:** Total-Body Irradiation
- **PROCEDURE:** Donor Lymphocyte Infusion
- **DRUG:** Cyclophosphamide
- **DRUG:** Tacrolimus
- **DRUG:** Mycophenolate Mofetil
- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation

## Key facts

- **NCT ID:** NCT03032783
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-31
- **Primary completion:** 2025-12-02
- **Final completion:** 2025-12-02
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03032783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03032783, "A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT03032783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*